Gujarat Themis Biosyn Ltd share price logo

Gujarat Themis Biosyn Ltd Share Price (GUJTHEM)

₹400.61.09%

as on

| Source : NSE

bell
The current prices are delayed by 15 mins, login to check live prices.

Gujarat Themis Biosyn Ltd Stock Performance

as on August 22, 2025 at 4:01 PM IST

  • Day's Low

    Day's High

    ₹388.2
    ₹404
    downward going graph

    3.10%

    Downside

    0.85%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    ₹208
    ₹405
    downward going graph

    48.08%

    Downside

    1.10%

    Upside

    downward going graph
Previous Close₹396.30
Open₹396.30
Volume1.74L
Upper Circuit₹475.55
Lower Circuit₹317.05
Day's Low388.2
Day's High404
52 Week Low208
52 Week High405
1 Month Return+ 6.4 %
3 Month Return+ 25.61 %
1 Year Return+ 15.17 %
3 Year Return+ 488.16 %
5 Year Return+ 1403.41 %

Gujarat Themis Biosyn Ltd Stock Fundamentals & Key Indicators

Check Gujarat Themis Biosyn Ltd market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

₹4,318.29 Cr

Return on Equity (ROE)

21.69

PE Ratio (TTM)

0

Return on capital employed (ROCE)

27.21

Beta (LTM)

-4.5

P/B Ratio

14.29

Dividend Yield

0

PEG Ratio

0

Quarterly Earnings Growth YOY

-31.57

EPS (TTM)

0

Sector

Pharmaceuticals

Book Value

0

Technical Analysis

Gujarat Themis Biosyn Ltd Stock's Interest Amongst Investors

-16%

Period Aug 23, 2025 to Jul 24, 2025. Change in 30 Days vs previous period

Search interest for Gujarat Themis Biosyn Ltd Stock has decreased by -16% in the last 30 days, reflecting a downward trend in search activity.

Gujarat Themis Biosyn Ltd Financial Results

Get the annual and quarterly financial summary of Gujarat Themis Biosyn Ltd, including revenue, profit, loss and more.

Value in ₹ crore
DetailsQ1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26
Revenue

(in ₹ Cr)

39 (0%)35 (11%)40 (14%)38 (4%)36 (5%)
Net Income

(in ₹ Cr)

13 (0%)11 (20%)13 (23%)12 (7%)9 (24%)
Net Profit Margin34.10% (0%)30.44% (11%)32.82% (8%)31.80% (3%)25.26% (21%)
Value in ₹ crore
DetailsFY21FY22FY23FY24
Total Assets

(in ₹ Cr)

89 (0%)123 (39%)167 (36%)222 (33%)
Total Liabilities

(in ₹ Cr)

19 (0%)20 (5%)18 (10%)20 (15%)
Value in ₹ crore
DetailsFY20FY21FY22FY23FY24
Operating Cash Flow

(in ₹ Cr)

1 (0%)11 (1571%)40 (283%)39 (2%)64 (63%)

Gujarat Themis Biosyn Ltd Earnings and Dividends

View detailed summary of the earnings and dividend history of Gujarat Themis Biosyn Ltd.

  • Gujarat Themis Biosyn Ltd Earnings Results

    Gujarat Themis Biosyn Ltd’s net profit fell -31.57% since last year same period to ₹9.06Cr in the Q1 2025-2026. On a quarterly growth basis, Gujarat Themis Biosyn Ltd has generated -24.5% fall in its net profits since last 3-months.

    Read More about Earnings Results
  • Gujarat Themis Biosyn Ltd Dividends May,2024

    In the quarter ending March 2024, Gujarat Themis Biosyn Ltd has declared dividend of ₹0.25 per share on 14 May 2024 - translating a dividend yield of 0.25%.

    Read More about Dividends

Indices Featuring Gujarat Themis Biosyn Ltd Stock

Check stock indices that include Gujarat Themis Biosyn Ltd.

BSE Healthcare

₹44,807.68

0.09 (40.48%)

BSE Small-Cap

₹53,002.32

-0.35 (-183.71%)

Gujarat Themis Biosyn Ltd Stock Shareholding Pattern

View the shareholding pattern breakup of promoters, FIIs, DIIs, and retail investors in Gujarat Themis Biosyn Ltd.

InvestorsHoldings %Quarterly Trend3M change
Promoter Holdings
70.86%
0.00
Foreign Institutions
2.51%
31.35
Mutual Funds
1.16%
0.01
Retail Investors
25.45%
-2.30
Others
0.01%
0.00

Gujarat Themis Biosyn Ltd vs Peers

Compare market cap, revenue, PE, and other key metrics of Gujarat Themis Biosyn Ltd with its industry peers.

Company
Analyst View
Market Cap(in ₹ Cr)
5 Year CAGRDebt to Asset Ratio
Net Profit(in ₹ Cr)
Yearly Revenue(in ₹ Cr)
NA4,318.29280.68%0.0048150
NA144.7017.83%0.847339
NA509.1222.09%0.00NANA
NA732.0831.15%0.514211,280
NA6.03-7.89%0.00-6NA

Gujarat Themis Biosyn Ltd News & Key Events

Latest news and events in one place to help you make informed investing decisions in Gujarat Themis Biosyn Ltd.

  • Gujarat Themis Reports Decline in Profit and Sales - 01 Aug, 2025

    Gujarat Themis Biosyn's standalone net profit for June 2025 fell 31.54% to Rs 9.06 crore, with sales down 7.61% to Rs 35.87 crore compared to the previous year.

Insights on Gujarat Themis Biosyn Ltd

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    FII Holding Up

    img

    Foreign Institutions have increased holdings from 1.91% to 2.51% in Jun 2025 quarter

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 7 days, GUJTHEM stock has moved up by 9.7%

  • imgNO EFFECT

    Promoter Holding Unchanged

    img

    Promoters holdings remained unchanged at 70.86% of holdings in Jun 2025 quarter

  • imgNEGATIVE IMPACT

    Retail Holding Down

    img

    Retail Investor have decreased holdings from 26.05% to 25.45% in Jun 2025 quarter

About Gujarat Themis Biosyn Ltd

GTBL was established in Dec.81 as a public limited company. Starting with the manufacturing of antibiotic erythromycin, it obtained licence in 1990 to produce bulk drugs like rifampicin, cephalexin, and griseofulvin with their formulations. From 1991, it faced several issues, thus making it a BIFR (Board of Industrial and Financial Reconstruction) case. It was then taken over by a group of investors – Lyka Labs, Themis Chemicals, Kopran, Cadila, and Yuhan Corporation (South Korea). In 1995-1996, they increased their paid up capital to Rs 11.60 crores after allotment of 350000 equity shares of Rs 10 each at a premium of Rs 20 per share to the financial institutions. This was followed by an increase in the installed capacity of rifamycinS to 90 mtpa and expansion of rifampicin to maximum capacity of 120 mtpa. They further launched a wide range of antituberculosis products and other antibiotics. They are focused on further diversifying and expanding their existing products and capacities with the scope to reduce production costs and increase turnover.

Revenue: ₹35.87Cr as on June 2025 (Q1 FY26)
Net Profit: ₹9.06Cr as on June 2025 (Q1 FY26)
Listing date: 01 Jun, 1995
Chairperson Name: Dinesh S Patel
OrganisationGujarat Themis Biosyn Ltd
HeadquartersMumbai
IndustryPharmaceuticals
CEODinesh S Patel
E-voting on sharesClick here to vote

Mutual Funds that own Gujarat Themis Biosyn Ltd Stock

Check out the Mutual Funds with significant holdings in Gujarat Themis Biosyn Ltd.

FAQs

What is Gujarat Themis Biosyn Ltd share price today?

Gujarat Themis Biosyn Ltd share price today stands at ₹400.6, Open: ₹396.3, Previous Close: ₹396.3, High: ₹404, Low: ₹388.2, 52 Week High: ₹405, 52 Week Low: ₹208 as on .

How to buy Gujarat Themis Biosyn Ltd shares ?

To buy Gujarat Themis Biosyn Ltd shares, you need to follow these steps:

  • Open a Demat account and Trading account on INDmoney
  • Fund your Trading account
  • Search for GUJTHEM or Gujarat Themis Biosyn Ltd on the INDmoney app to check live prices of the stock
  • Click on Buy or SIP to place an order to invest in Gujarat Themis Biosyn Ltd shares. You can invest by selecting the number of shares or set up a fixed SIP to invest every month or week.

What is today's traded volume of Gujarat Themis Biosyn Ltd?

Today's traded volume of Gujarat Themis Biosyn Ltd is 1.74L. Which means that 1.74L shares of Gujarat Themis Biosyn Ltd were bought and sold on the stock market during today's trading session.

What is Gujarat Themis Biosyn Ltd's market cap today?

Today's market capitalisation of Gujarat Themis Biosyn Ltd is ₹4,318.29 Cr. Market cap or market capitalisation is the total value of a company’s outstanding shares in the stock market, calculated by multiplying the current share price by the total number of shares issued by the company.

What is the 52 week high and 52 week low range of Gujarat Themis Biosyn Ltd?

Gujarat Themis Biosyn Ltd’s 52 week high is ₹405 and 52 week low is ₹208. The current share price of Gujarat Themis Biosyn Ltd is ₹400.6, which is -1.09% down from its 52 week high and 92.60% up from its 52 week low.